studi
design
method
merscov
emc
strain
use
inocul
plasma
unit
underw
treatment
riboflavin
uv
light
infecti
titer
merscov
sampl
treatment
determin
plaqu
assay
vero
cell
treatment
initi
perform
triplic
use
pool
plasma
n
repeat
use
individu
plasma
unit
n
studi
riboflavin
uv
light
reduc
infecti
titer
merscov
limit
detect
mean
log
reduct
viral
titer
pool
individu
donor
plasma
respect
conclus
riboflavin
uv
light
effect
reduc
titer
merscov
human
plasma
product
limit
detect
suggest
treatment
process
may
reduc
risk
transfus
transmiss
merscov
middl
eastern
respiratori
syndrom
coronaviru
merscov
first
identifi
like
zoonot
transmiss
event
camel
merscov
caus
sever
lower
respiratori
tract
infect
result
pneumonia
multiorgan
failur
particularli
patient
underli
comorbid
elderli
septemb
saudi
arabian
ministri
health
report
case
merscov
infect
fatal
largest
outbreak
merscov
outsid
arabian
peninsula
occur
republ
korea
mayjuli
accord
world
health
organ
confirm
case
death
transmiss
merscov
extens
document
hospit
set
saudi
arabia
korea
index
case
enter
health
care
system
greatest
impact
merscov
date
abroad
two
document
case
travel
report
unit
state
thu
reason
expect
merscov
continu
emerg
unit
state
travel
health
care
worker
enter
countri
return
home
although
nosocomi
merscov
infect
occur
evid
date
merscov
transmit
transfus
blood
product
health
care
set
similar
observ
outbreak
sever
acut
respiratori
syndrom
sar
caus
anoth
member
coronaviru
famili
sarscov
outbreak
viral
rna
detect
symptomat
patient
serum
howev
date
blood
transfus
implic
viral
transmiss
unclear
whether
viral
rna
present
serum
indic
possibl
asymptomat
virem
phase
could
lead
possibl
transfus
transmiss
despit
lack
direct
evid
transfus
transmiss
risk
merscov
coronavirus
merscov
identifi
agent
pose
exist
potenti
threat
blood
safeti
aabb
current
merscovspecif
screen
question
donor
deferr
period
recommend
aabb
mirasol
pathogen
reduct
technolog
prt
system
develop
provid
ad
layer
protect
help
prevent
transmiss
exist
emerg
pathogen
merscov
transfus
human
blood
product
mirasol
prt
system
broadspectrum
pathogenreduct
process
shown
effect
reduc
infect
bloodborn
bacteria
parasit
virus
system
combin
riboflavin
photosensit
ultraviolet
uv
light
irrevers
damag
nucleic
acid
blood
product
result
dnarna
damag
prevent
pathogen
white
blood
cell
replic
affect
nonrepl
cell
like
platelet
red
blood
cell
maintain
accept
plasma
protein
qualiti
posttreat
purpos
studi
evalu
efficaci
mirasol
prt
system
reduct
merscov
emc
strain
human
plasma
product
use
pool
plasma
individualdonor
plasma
unit
plasma
product
collect
accredit
blood
bank
institut
review
board
approv
ship
terumo
bct
unit
consist
recov
plasma
frozen
within
hour
collect
two
set
plasma
use
experi
preliminari
studi
limit
number
replic
perform
determin
whether
riboflavin
uv
light
treatment
inactiv
merscov
perform
use
pool
plasma
unit
n
verif
studi
use
replic
follow
individu
donor
plasma
unit
n
use
riboflavin
uv
light
process
previous
describ
detail
briefli
ml
human
plasma
dispens
extendedlif
platelet
elp
illuminationstorag
bag
mix
ml
riboflavin
solut
mmoll
riboflavin
sodium
chlorid
ph
terumo
bct
riboflavinplasma
mixtur
inocul
viru
sampl
place
mirasol
illumin
terumo
bct
uv
treatment
plasma
unit
expos
jml
energi
merscov
viru
level
pathogen
mirasol
illumin
use
level
laboratori
fill
plasma
bag
briefli
immers
bleach
illumin
ensur
live
viru
adher
outsid
elp
bag
affect
light
transmiss
properti
elp
bag
viru
reduct
studi
perform
colorado
state
univers
preliminari
studi
ml
pool
plasma
product
riboflavin
inocul
ml
merscov
stock
plaqu
form
unit
pfu
ml
mix
sampl
obtain
held
ambient
temperatur
pretreat
sampl
treatment
riboflavin
uv
light
second
sampl
obtain
posttreat
sampl
pretreat
posttreat
sampl
serial
dilut
medium
minimum
essenti
medium
supplement
bovin
serum
albumin
viral
titer
test
duplic
use
plaqu
assay
vero
cell
neat
dilut
plate
previou
work
demonstr
plasma
cytotox
effect
vero
cell
data
shown
verif
studi
singledonor
plasma
unit
riboflavin
inocul
ml
merscov
pfuml
sampl
remov
unit
treatment
measur
viru
titer
pretreat
sampl
serial
dilut
medium
dilut
test
use
plaqu
assay
vero
cell
posttreat
sampl
dilut
test
triplic
use
plaqu
assay
vero
cell
increas
assay
sensit
neat
dilut
plate
previou
work
demonstr
plasma
cytotox
effect
vero
cell
data
shown
briefli
plaqu
assay
confluent
vero
cell
monolay
grown
sixwel
plate
well
inocul
ml
dilut
plasma
sampl
plate
rock
everi
minut
minut
overlaid
agaros
medium
incub
day
co
day
second
overlay
contain
neutral
red
ad
plaqu
count
follow
day
viru
titer
determin
base
plaqu
number
dilut
viru
use
experi
lowpassag
human
isol
merscov
strain
propag
vero
cell
cultur
dulbecco
modifi
eagl
medium
fetal
bovin
serum
describ
previous
viru
stock
maintain
thaw
use
posttreat
sampl
neg
presenc
viru
limit
detect
reach
valu
limit
detect
consid
less
equal
calcul
limit
detect
theoret
limit
detect
calcul
use
follow
equat
n
lowest
number
particl
product
detect
confid
p
probabl
viru
undetect
confid
detect
viru
p
v
total
volum
treat
product
plasma
riboflavin
viru
v
volum
use
viral
enumer
volum
inoculatedwel
ml
number
replic
well
lowest
dilut
inocul
inactiv
merscov
viru
riboflavin
uv
light
evalu
merscov
repres
emerg
pathogen
caus
concern
regard
transfus
transmiss
work
perform
vitro
plaqu
assay
use
measur
infecti
viral
load
efficaci
riboflavin
uv
light
merscov
first
evalu
triplic
use
pool
plasma
sampl
tabl
mean
reduct
log
viral
titer
notabl
across
three
replic
assay
reduc
observ
viral
titer
limit
detect
log
pfuml
demonstr
efficaci
riboflavin
uv
light
pool
plasma
net
reduct
merscov
individualdonor
plasma
unit
n
assess
result
summar
tabl
mean
standard
deviat
reduct
viral
titer
log
like
pool
plasma
viru
titer
reduc
limit
detect
log
pfuml
six
individualdonor
plasma
unit
although
document
case
transfus
transmiss
merscov
one
pathogen
cite
specif
agent
concern
aabb
use
riboflavin
uv
lightbas
treatment
reduc
infecti
titer
merscov
limit
detect
plasma
unit
test
mean
log
reduct
merscov
titer
exceed
european
committe
blood
transfus
recommend
state
consid
effect
pathogenreduct
process
reduc
screen
pathogen
least
log
studi
conduct
corman
colleagu
indic
merscovinfect
patient
may
viral
load
log
rna
copiesml
serum
howev
author
also
indic
viru
appear
infecti
cell
cultur
suggest
transfus
transmiss
unlik
although
observ
reduct
merscov
evalu
plasma
product
safe
assum
extend
platelet
product
basi
previou
research
use
mirasol
prt
system
demonstr
pathogenreduct
system
caus
minor
chang
platelet
compromis
hemostat
efficaci
platelet
transfus
howev
also
decreas
risk
graftversushost
diseas
improv
shelf
life
taken
togeth
result
studi
suggest
riboflavin
uv
light
might
abl
reduc
likelihood
merscov
transfus
transmiss
platelet
plasma
product
infecti
viru
present
blood
asymptomat
donor
pathogen
identifi
aabb
concern
blood
safeti
base
likelihood
transmiss
transfus
clinic
diseas
transfus
recipi
press
concern
relat
diseas
known
transfus
transmiss
event
sever
fatal
outcom
eg
dengu
viru
babesia
parasit
creutzfeldtjakob
prion
target
screen
process
identifi
blood
product
contain
potenti
transmiss
pathogen
markedli
improv
overal
safeti
transfus
howev
although
rare
transfus
transmiss
even
wellknown
pathogen
like
human
immunodefici
viru
hiv
still
occur
unit
state
resourcelimit
set
like
africa
mani
new
hiv
case
link
transfusiontransmit
infect
target
screen
program
limit
part
increment
natur
updat
pathogen
list
knowledg
pathogen
recent
estim
known
human
pathogen
zoonot
consid
emerg
reemerg
pathogen
known
pathogen
concern
blood
safeti
one
estim
novel
virus
discov
year
virus
anim
origin
target
screen
scale
econom
logist
feasibl
keep
pace
emerg
threat
blood
safeti
pathogenreduct
system
potenti
complementari
approach
blood
screen
program
may
potenti
replac
screen
assay
like
cytomegaloviru
west
nile
viru
riboflavin
uv
light
alreadi
establish
efficaci
broad
array
viral
pathogen
differ
virus
includ
influenza
hiv
west
nile
viru
result
current
studi
support
find
riboflavin
uv
light
effect
inactiv
coronavirus
addit
broad
spectrum
envelop
nonenvelop
virus
alreadi
test
riboflavin
uv
light
effect
reduc
titer
merscov
human
plasma
product
limit
detect
use
vitro
cell
cultur
model
expand
list
pathogen
effect
reduc
technolog
addit
infecti
merscov
discov
blood
asymptomat
donor
riboflavin
uv
light
would
reduc
likelihood
transfus
transmiss
platelet
plasma
product
